Agennix, a company associated with Baylor College of Medicine, Texas, makes a 
recombinant form of human lactoferrin for use in wound healing.  This is 
based on research on human milk and its properties.  They are doing clinical 
trials.  There are a number of patents but human milk component patenting is 
off-topic on this list.
Valerie W. McClain 
http://www.agennix.com/
"Recombinant human lactoferrin (rhLF) is identical in all material respects 
to native lactoferrin. As a result of this new technology, Agennix' lactoferrin 
is now in Phase II human clinical trials for the treatment of cancer and 
diabetic wounds."

             ***********************************************

To temporarily stop your subscription: set lactnet nomail
To start it again: set lactnet mail (or digest)
To unsubscribe: unsubscribe lactnet
All commands go to [log in to unmask]

The LACTNET mailing list is powered by L-Soft's renowned
LISTSERV(R) list management software together with L-Soft's LSMTP(R)
mailer for lightning fast mail delivery. For more information, go to:
http://www.lsoft.com/LISTSERV-powered.html